Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and ...
NextCure (NXTC) reported pre-clinical data from LNCB74, a B7-H4-targeting antibody-drug conjugate, or ADC, being developed in partnership with ...
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores ...
At CPHI Milan 2024, Abzena showcased its latest innovations in cell line development and ADC manufacturing, featuring the ...
Scarring of heart tissue can be slowed but not stopped, and can lead to heart failure. But a new study has shown that an ...
Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by ...
DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...
Q3 2024 Earnings Call Transcript November 6, 2024 Coherus BioSciences, Inc. beats earnings expectations. Reported EPS is ...
One of this year’s Nobel Prize winners in physics, Geoffrey Hinton, who pioneered work on the neural networks that undergird artificial intelligence, has warned that machines might someday get smarter ...
On November 1, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as 'Chipscreen Biosciences') and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceutical Ltd., received the ...
Scientists have devised new types of chimeric antigen-receptor (CAR) T cells -- a type of cancer immunotherapy -- that can be switched on to varying degrees of intensity and then switched off on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback